Key Facts · 2026-09-27
- Under EC 1223/2009, an own-label range in the EU needs a named Responsible Person, a Product Information File and a CPNP notification before the first pallet ships.
- Retailers keep more margin on own label than on third-party lines, and a Product Information File must be retained for 10 years after the last batch ships.
- Face creams are typically quoted at 1,000-2,000 units per SKU and serums at 1,000-3,000 units, so every item on a pharmacy line carries a real volume commitment.
- Each product sold in the EU must be notified through CPNP under Regulation 1223/2009 before it reaches a European market, and the label language must match the market where it retails.
- Localising a formula to Germany or France means re-aligning it to local water hardness, climate and INCI expectations, adding 2-4 weeks of sampling to the calendar.
- Pharmacy onboarding usually asks for stability data and a dermatologically tested claim before a listing is confirmed, which gates a 3-5 month development path.
The Margin Structure That Explains the Whole Category
A pharmacy or drugstore brand is priced very differently from a mass-market one. Rebates, listing fees and marketing contributions reduce the headline margin on third-party lines, while an own-label product carries none of those deductions. That single difference is why category managers in Germany and Austria keep carving out shelf space for their own ranges.
The catch is that the retailer absorbs the development cost instead of the supplier. A first line usually runs into six figures across formulation, compliance and packaging, and the retailer only recoups it once the range has wide distribution.
Category managers are not buying a product. They are buying the difference between what they pay and what the shelf earns.
What Actually Moves Units on a Pharmacy Shelf
In European pharmacy and para-pharmacy channels, three things predict whether an own-label line will be re-ordered. The first is claim restraint. The second is ingredient legibility, since shoppers on these shelves read INCI lists and expect to recognise actives. The third is pack size, because a 30 ml serum and a 50 ml cream are treated as different price decisions.
None of those are formulation problems in the laboratory sense. They are formulation problems in the sense of what you are allowed to say and what a pharmacist will repeat to a customer.
Why the Formula Has to Be Localised, Not Just Translated
A formula developed for one market rarely performs identically in another. Water hardness, average humidity and the local weather profile all change how a moisturiser feels on skin, and German customers in particular respond to texture descriptions they can verify on their own skin within a week of use.
Localisation also means checking that the preservative system and the claims you intend to make are compatible with the marketing language used in that country. A claim that is safe in one market can be too strong in another, which is a formulation change rather than a copy change.
Compliance Is a Prerequisite Spend, Not an Afterthought
Before a single pallet reaches a European pharmacy distribution centre, three things must already exist. The supplier needs to have appointed a Responsible Person under EC 1223/2009, a Product Information File must be compiled for every SKU, and each formulation needs a CPNP notification filed in the market where it will be sold.
Wholesalers and pharmacy groups increasingly ask for that documentation at onboarding rather than at first order. A range that arrives without it will sit in the yard while the retailer's category manager waits.
- Appoint a Responsible Person and confirm in writing who holds the compliance duty for each brand.
- Compile a Product Information File per SKU, covering formulation, manufacturing site, stability data and packaging.
- File a CPNP notification per product before the first sale in each European market.
- Run stability testing and a preservative challenge test early, because the period-after-opening number depends on them.
- Verify pack sizes against local pharmacy norms before committing to a 1,000-2,000 unit run.
What a Launching Chain Looks Like in Practice
A European drugstore chain planning its own-label entry typically starts with a restrained core: one micellar cleanser, one niacinamide serum, one barrier cream and one SPF. Those four SKUs sit at the low end of the complexity curve and cover the most frequently repurchased categories on the shelf.
The next twelve months usually add an anti-ageing line at 2,000-4,000 units per SKU, which is where the retailer starts recovering its development investment. The chain that treats year one as a data-collection exercise rather than a profit statement is the one that ends up with a defensible second line.
For suppliers, the read is straightforward: the European pharmacy channel rewards compliance maturity and restraint in claims far more than it rewards novelty.
- Start with repurchase-heavy basics where the volume is predictable.
- Keep claims modest so a pharmacist can repeat them without hesitation.
- Budget compliance before goods, because it gates the listing rather than following it.
The pharmacy channel rewards compliance maturity and claim restraint far more than it rewards novelty.
Frequently Asked Questions
Pitch your own-label range with the paperwork ready
Send us your target pharmacy or drugstore group, pack sizes and intended claims. We will return MOQ ranges, stability timing and the compliance file we can compile for you.
Start your match